Leafwell Publishes New PTSD Study, Builds on Evidence Supporting Medical Cannabis for …
#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
# Clinical Summary This study contributes to the growing body of evidence supporting medical cannabis as a therapeutic option for post-traumatic stress disorder, building on previous research from the same group examining cannabis use in chronic pain populations. The research appears to characterize patient outcomes and symptom improvements in individuals with PTSD who have accessed cannabis through clinical channels, adding real-world data to complement controlled trials in this indication. For clinicians, this adds observational evidence relevant to informed discussions with PTSD patients about potential symptom management options, particularly for those who have not responded adequately to first-line psychotherapy and pharmacotherapy. The integration of cannabis research into mainstream clinical dialogue through platforms bridging patients and healthcare providers reflects the evolving landscape where some patients are accessing cannabinoid therapies and clinicians need current evidence to guide counseling and monitoring. Clinicians should recognize that while such evidence is accumulating, PTSD treatment decisions should continue to follow established guidelines with cannabis considered as part of a comprehensive treatment strategy rather than a monotherapy, with appropriate assessment of individual risk factors and careful documentation of symptom response.
“I appreciate that observational data from patient registries like Leafwell’s can help identify patterns worth investigating further, but we need to be clear about the limitations – these aren’t randomized controlled trials, and patient self-selection and reporting bias are real concerns. The signal for PTSD symptom relief is interesting enough that it warrants rigorous clinical trials, but until we have that level of evidence, I’m cautious about drawing firm conclusions for individual patient care.”
🧠 While observational data from commercial cannabis platforms like Leafwell documenting patient-reported symptom improvements in PTSD are encouraging, clinicians should recognize important limitations when considering these findings for practice. Studies conducted or published by cannabis retailers inherently carry sponsorship bias, lack the rigorous controls of randomized trials, and typically capture only patients with access to their services and willingness to self-report outcomes—populations that may differ meaningfully from the broader PTSD population. Current evidence for cannabis in PTSD remains mixed, with robust data primarily supporting evidence-based treatments like prolonged exposure therapy and cognitive processing therapy, which maintain stronger safety and efficacy profiles. Given these constraints, practitioners may acknowledge patient interest in cannabis while emphasizing that any consideration should occur within a comprehensive treatment plan that includes first-line psychotherapies and pharmacotherapies, with close monitoring for potential adverse effects including symptom exacerbation in some individuals.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
